Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by STROM, B. L
Right arrow Articles by STOLLEY, P. D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by STROM, B. L
Right arrow Articles by STOLLEY, P. D
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1985 Oxford University Press

research-article

No Evidence of Association Between Methyldopa and Biliary Carcinoma

BRIAN L STROM, PATRICIA L HIBBERD and PAUL D STOLLEY

Clinical Epidemiology Unit, Section of General Medicine,Departments of Medicine and Pharmacology, University of Pennsylvania School of Medicine Philadelphia, Pennsylvania 19104

Reprint requests to: Brian L Strom, 225L NEB/S2, Clinical Epidemiology Unit, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104.

Strom B L (Clinical Epidemiology Unit, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19104, USA), Hibberd P L and Stolley P D. Noevidence of association methyldopa and biliary carcinoma. International Journal of Epidemiology 1985, 14:86-90.

Cancer of the bile ducts is rare and little is known about its risk factors. Recently, an association between methyldopa therapy and biliary carcinoma was reported in a retrospective case-control study. If this association were real, it would represent a significant health hazard, because methyldopa is widely prescribed. Using analysis of covariance to study the relationship between biliary tract cancer rates (obtained from 11 cancer registries in the US, Canada, Europe, and Asia) and per capita methyldopa sales (obtained from its manufacturer), this possible association was re-examined. For the rates of all biliary tract cancers combined, using both three- and ten-year lag periods between drug sales and disease, there were no associations between methyldopa and biliary carcinoma. When the rates for the biliary tract cancer sites were examined separately, one small positive regression coefficient was observed with extrahepatic biliary tract cancer, using the ten-year lag period only (p=0.03). Since the majority of biliary tract cancers are extrahepatic in origin, it is likely that most of the cancers coded as ‘biliary tract cancer, part unspecified’ are actually extrahepatic. Also, the magnitude of the slope is very small, contrary to what one would expect with a common drug exposure and an uncommon disease. For these reasons, we believe that the negative results obtained with the combined rates for biliary tract cancer are more meaningful than the results obtained for each cancer site separately. In conclusion, our data do not support the presence of an association between methyldopa and biliary tract cancer.

Revised 1 March 1984


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
E Grossman, F.H Messerli, and U Goldbourt
Antihypertensive therapy and the risk of malignancies
Eur. Heart J., August 1, 2001; 22(15): 1343 - 1352.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.